CXM Financial Facts

Interest expense: 1.17K
Net loss: -609.43K
See Full Income Statement

Deficit accumulated during development stage: -111.44M
Current liabilities: 2.72M
See Full Balance Sheet

Cardium Therapeutics, Inc. (CXM) Earnings

  |   Expand Research on CXM
Next EPS Date N/A EPS Growth Rate N/A
Average EPS % Beat Rate -21.3% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS 0.0% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/14/13 Q212 -$0.37-$0.20 -$0.17$584.57K$1M N/A Details
5/15/12 Q112 -$0.02N/A N/A N/AN/A N/A Details
3/30/12 Q411 -$0.02N/A N/A N/AN/A N/A Details